Lexology May 29, 2024
Arthur Cox LLP

The Act, which was approved in the United States this month, prohibits executive agencies (“EA”) from contracting with or providing financial assistance to “biotechnology companies of concern” (“BCOC”) or any companies who have commercial arrangements with BCOC. The Act defines BCOC and specifically names companies such as RPC-BGI, MGI, Complete Genomics, WuXi Apptec and their affiliates.

The Act also defines an EA as “an Executive department, a government corporation, and an independent establishment” including the Department of Defence, the Department of Energy and the Department of Health and Human Services, which houses agencies such as the Food and Drug Administration, the Centre for Disease Control and the National Institutes of Health.

The objective of the Act is to reduce EAs’...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma / Biotech, Regulations
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups
AI Tech Firm SandboxAQ Adds $300M to Ramp Up Development of LQMs for Drug Discovery & More

Share This Article